Takeda Completes Acquisition and Names New CEO of Nycomed

Osaka, Japan (ots/PRNewswire) -

Takeda Pharmaceutical Company Limited announced it has completed
its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a
cash-free, debt-free basis and made Nycomed a wholly owned subsidiary
of Takeda effective the same day. Dr. Frank Morich has been named CEO
of Nycomed in addition to his current role as Executive Vice
President (EVP), International Operations (Americas/Europe), Takeda
Pharmaceuticals International, Inc., a wholly owned subsidiary of
Takeda America Holdings, Inc.

The transaction fits in with Takeda's sustainable growth strategy
outlined in its 2011-2013 Mid-Range Plan (MRP). Takeda has a strong
presence in the Japanese and U.S. markets, while Nycomed has a
significant business infrastructure in Europe and high-growth
emerging markets that will enhance Takeda's regulatory development
expertise and commercialization capability. In addition, the
acquisition will bring Takeda an immediate and stable increase in
cash flow generated from annual revenue of more than 2.8 billion Euro
from the acquired business.

"The combination of both organizations will strengthen Takeda's
performance during the 2011-2013 MRP period, and enable us to sustain
medium and long-term growth targets starting in fiscal 2015 and
extending into the next decade," said Yasuchika Hasegawa, President &
CEO of Takeda. "Partnering the two organizations will have
complementary effects and further increase our potential to become a
truly global pharmaceutical company."

"I look forward to bringing Takeda and Nycomed together to ensure
we can achieve enhanced revenue, growth and diversification, while
maintaining the strong momentum of both companies," said Frank
Morich. "The combined company significantly broadens our coverage of
the global pharmaceutical market to more than 70 countries,
increasing our global Rx sales ranking to 12th and further
strengthening our position in the industry."

The combined company will have an active commercial presence in
the therapeutic areas of metabolic diseases, gastroenterology,
oncology, cardiovascular health, CNS diseases, inflammatory and
immune disorders, respiratory diseases and pain management, as well
as having a well-balanced presence in pharmaceutical markets of
Japan, North America, Europe and Asia/Emerging Markets.

The integration enhances the 1,260 billion yen of projected FY
2013 sales in 2011-13 MRP by more than 30 percent and improves the
280 billion yen of projected FY 2013 operating income (excluding
special factors derived from business acquisition) in 2011-13 MRP by
more than 40 percent. Takeda will now start preparation of the
consolidated financial outlook for its fiscal 2011 ending March 31,
2012, and is planning to announce it upon announcement of its
financial results of fiscal 2011 2Q scheduled in November.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global
company with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to strive towards better health for
patients worldwide through leading innovation in medicine. Additional
information about Takeda is available through its corporate website,
http://www.takeda.com.

Takeda's Forward-looking statements

This press release contains forward-looking statements.
Forward-looking statements include statements regarding Takeda's
plans, outlook, strategies, results for the future, and other
statements that are not descriptions of historical facts.
Forward-looking statements may be identified by the use of
forward-looking words such as "may," "believe," "will," "expect,"
"project," "estimate," "should," "anticipate," "plan," "assume,"
"continue," "seek," "pro forma," "potential," "target," "forecast,"
"guidance," "outlook" or "intend" or other similar words or
expressions of the negative thereof. Forward-looking statements are
based on estimates and assumptions made by management that are
believed to be reasonable, though they are inherently uncertain and
difficult to predict. Investors are cautioned not to unduly rely on
such forward-looking statements.

Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements. Some of
these risks and uncertainties include, but are not limited to, (1)
the economic circumstances surrounding Takeda's business, including
general economic conditions in Japan, the United States and
worldwide; (2) competitive pressures and developments; (3) applicable
laws and regulations; (4) the success or failure of product
development programs; (5) actions of regulatory authorities and the
timing thereof; (6) changes in exchange rates; (7) claims or concerns
regarding the safety or efficacy of marketed products or product
candidates in development; and (8) integration activities with
acquired companies.

The forward-looking statements contained in this press release
speak only as of the date of this press release, and Takeda
undertakes no obligation to revise or update any forward-looking
statements to reflect new information, future events or circumstances
after the date of the forward-looking statement. If Takeda does
update or correct one or more of these statements, investors and
others should not conclude that Takeda will make additional updates
or corrections.

Takeda Media and Investor Contacts:
For Japanese Media and Global IR Inquiries:
Seizo Masuda
+81-3-3278-2037
masuda_seizo@takeda.co.jp
For Media Inquiries:
Rebekah Childers
Takeda
+44(0)780-949-5101
r.childers@tgrd.com
Tobias Cottmann
Nycomed
+41-79-2177252
tobias.cottmann@nycomed.com

ots Originaltext: Takeda Pharmaceutical Company Limited
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.